Flow Neuroscience is a Neuromodulation & Stimulation company founded in 2016 and based in London, United Kingdom. It has raised $9.3M in total funding, most recently a Series A in 2021.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Aug 11, 2021 | Series A | $9.3M | — | Khosla Ventures |
No articles ingested yet for Flow Neuroscience. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
At-home transcranial direct current stimulation (tDCS) device that delivers gentle electrical current to the prefrontal cortex to treat major depressive disorder, combined with a behavioral therapy app. FDA-cleared in December 2025 as the first non-drug, at-home device approved for depression treatment in the US. Previously available in Europe as a CE-marked Class IIa device since 2019 with 55,000+ units sold. Clinical trial showed 58% remission rate at 10 weeks, two to three times higher than sham treatment.
10 patents on file, but none with both an extractable figure and an abstract on Google Patents yet.